Some hopeful news for those suffering from systemic lupus erythematosus (SLE) has been revealed as of late. The European League Against Rheumatism (EULAR), representing those with arthritis/rheumatism, scientific societies of rheumatology amongst European nations, and health professionals, recently held an annual congress, where something interesting was announced. Two analyses results from a Phase 2 study around Stelara® (ustekinumab) therapy were released offering some insight around the treatment as a sustained clinical benefit for management around SLE activity at a one-year time period, and a decrease in rate as it relates to the illness’ flare ups.
The first clinical study involved just over 100 adults dealing with lupus. Long-term figures around Stelara were offered, confirming a four-fold reduction when it came to severe flare up rates when groups were compared against the therapy and placebo.
The second study added a Stelara review of Phase 2, offering biomarker data. The results revealed that lupus sufferers who responded to the treatment had substantial decreased in IFN-y protein levels compared to “baseline” (a review that did not analyze participants who did not receive placebo or respond to Stelara). These study findings connect the involvement around new links that need additional research for a possible new lead to understanding lupus.
Additionally, the clinic trial was provided with a tool known as the Lupus Foundation of America REAL™ – Rapid Evaluation of Activity in Lupus (LFA-REAL), which analyses and measures the disease activity within lupus study patients.
This is a huge breakthrough for researchers who have tirelessly been analyzing the illness, doctors, and lupus patients themselves.
A long-term autoimmune condition, lupus occurs when a person’s immune system suffers from hyperactivity; attacking healthy and normal body tissue. Signs and symptoms include: swelling, inflammation, as well as damage to one’s skin, joints, kidneys, heart, lungs, and blood.
Across America, approximately 16,000 lupus cases emerge every year, with about 1.5 million in the U.S. living with the disease, currently.